Bristol Myers Squibb

BMS Staff Assemble 70+ Schizophrenia Support Kits in Saudi Arabia

Riyadh – October 12, 2026 -- Bristol Myers Squibb (BMS) employees in Saudi Arabia assembled and personalized more than 70 'Small Wins' toolkits for people living with schizophrenia, in partnership with the Saudi Schizophrenia Association ('Ehtiwaa'). The project was part of the 12th edition of BMS's annual Global Patient Week.

Ehtiwaa and BMS design a four-step kit to build daily motivation

The 'Small Wins: Everyday Activity & Motivation' toolkit guides patients through four steps: pick a card, try the activity, recognize the win, and add it to a jar. Each kit contains activity cards with optional suggestions such as listening to a favorite song, spending a few minutes outside or tidying one small space. A 'Small Wins Jar' with paper slips lets users record daily moments of joy. Each kit also carries a handwritten note from a BMS volunteer.

Global Coalition Launches 30x30x50 Challenge to Cut Stroke, Expand Screening

New York – October 05, 2026 -- A new multisector coalition launched the 30x30x50 Brain Challenge, pledging to cut stroke incidence by 30 percent and increase primary-care cognitive screening by 50 percent across 30 global cities by 2031.

Atria-coordinated coalition unites pharma, tech and the UN behind brain health delivery

The International Brain Health Coalition (IBC), coordinated by the Atria Research and Global Health Institute (ARGHI), brings together patients, multilateral institutions including the United Nations, and organizations spanning medicine, technology, and finance. Collaborators include Eli Lilly and Company, Bristol Myers Squibb, Microsoft, the Royal Bank of Canada, the American Heart Association, UN Women, Western University, and the AI-Mind Institute in Norway.

Bristol Myers Squibb Joins Rare Access Action Project Coalition

Washington – September 24, 2026 -- Bristol Myers Squibb (BMS) has joined the Rare Access Action Project (RAAP), adding a major biopharmaceutical player to a coalition working to resolve coverage and access barriers for rare disease patients.

RAAP expands coalition with BMS to tackle patient access barriers

RAAP, a coalition of patient advocates and life sciences companies, confirmed BMS's membership as part of its ongoing effort to develop policy solutions for structural access and coverage gaps affecting rare disease patients. Michael Eging, Executive Director of RAAP, said BMS brings a long history of scientific innovation and a strong commitment to patients facing serious and complex diseases.

BioMarin Adds Bristol Myers Squibb Research Chief Robert Plenge to Board

San Rafael, Calif. – September 18, 2026 -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) has appointed Robert Plenge, M.D., Ph.D., to its Board of Directors, effective September 18, 2026.

Plenge brings nine-site global research oversight from Bristol Myers Squibb

Dr. Plenge currently serves as Executive Vice President, Chief Research Officer and Head of Research at Bristol Myers Squibb, directing scientific operations across nine research sites worldwide. He joined the company in November 2019 through its acquisition of Celgene Corp., where he had led the immunology and inflammation portfolio in research and early development.

SystImmune's Iza-bren Hits Phase 3 Dose in Global Lung Cancer Trial

Seoul – September 17, 2026 -- SystImmune, Inc. announced that new global Phase 1 data support 2.5 mg/kg D1D8 Q3W as the recommended Phase 3 dose for iza-bren (izalontamab brengitecan), a bispecific EGFRxHER3 antibody drug conjugate, in previously treated EGFR-mutated metastatic non-small cell lung cancer (NSCLC).

Randomized Phase 1 cohort confirms higher efficacy at the 2.5 mg/kg dose level

The abstract, presented in an oral session at the IASLC 2026 World Conference on Lung Cancer (WCLC) in Seoul, South Korea, evaluated iza-bren across three dose levels in a randomized dose-expansion cohort. Patients enrolled had EGFR-mutated metastatic NSCLC and had previously received a third-generation EGFR inhibitor. Results showed promising antitumor activity with a manageable safety profile, with the highest efficacy observed at the 2.5 mg/kg dose.

CD&R Names Ex-BMS CEO Giovanni Caforio Operating Advisor

London – September 13, 2026 -- CD&R has appointed Giovanni Caforio, current Chair of Novartis and former CEO of Bristol Myers Squibb (BMS), as an Operating Advisor to its funds, tasking him with sourcing and evaluating healthcare investment opportunities globally.

Caforio brings 35 years of biopharmaceutical leadership to CD&R's healthcare strategy

Dr. Caforio has led Novartis' board since 2025 and previously spent over two decades at BMS after 12 years at Abbott Laboratories. He will support CD&R funds in identifying new healthcare deals and work directly with the firm's portfolio companies worldwide.

INBI Launches in Israel, Names Anat Cohen-Dayag CEO of Core Unit

Tel Aviv – – September 12, 2026 -- The Israel National Biotech Innovation Center (INBI) officially launched operations, uniting 15 of Israel's top universities, research institutions and healthcare organizations under a single translational platform for the first time.

Anat Cohen-Dayag Takes Helm of INBI Core

Anat Cohen-Dayag, PhD, Executive Chairperson of Compugen and formerly its President and CEO for 15 years, has been appointed Chief Executive Officer of INBI Core Ltd., the wholly owned operational subsidiary of INBI. Samuel Moed, former Senior Vice President of Corporate Strategy at Bristol Myers Squibb, will chair both INBI and INBI Core.